JHP Pharmaceuticals, a provider of global contract manufacturing services for sterile products has entered into an agreement with an undisclosed biotechnology company to produce clinical supplies of a biologic for late-phase clinical trials.
JHP’s cGMP compliance history was a critical factor in the selection process. Stuart Hinchen, CEO stated, “Our record of cGMP compliance, driven by experienced Quality and Regulatory Teams continues to be one of the key reasons customers choose JHP. Additionally, both new and established customers recognize our approach to ongoing investment in people and facilities. As an example, last year we broke ground on a new $10 million, 40,000 sq. ft. laboratory that will house QC Chemistry and Method Transfer, Sterility Assurance and Stability. This type of investment allows us to focus on customer needs, which results in sustainable sales growth.”
Hinchen noted, “Our use of disposable product contact equipment is another leading factor in the selection process. JHP’s strategic use of disposables provides our customers with manufacturing process efficiencies that result in reduced cycle time.”
